Patents Examined by Michelle Horning
-
Patent number: 7410979Abstract: The present invention relates to anti-HCV dihaloacetamide compounds in synergistic combination with an interferon and/or ribavirin and pharmaceutical compositions thereof for inhibition of the replication of HCV virus. The present invention also relates to the use of the compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.Type: GrantFiled: November 19, 2004Date of Patent: August 12, 2008Assignee: Rigel Pharmaceuticals, Inc.Inventor: Henry Lu
-
Patent number: 7405285Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.Type: GrantFiled: September 22, 2005Date of Patent: July 29, 2008Assignee: Idera Pharmaceuticals, Inc.Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
-
Patent number: 7371846Abstract: The invention relates to novel CD4-independent HIV Envelope proteins and uses therefor.Type: GrantFiled: February 1, 2005Date of Patent: May 13, 2008Assignee: The Trustees of the University of PennsylvaniaInventors: James A. Hoxie, Celia C. LaBranche, Robert W. Doms, Trevor L. Hoffman
-
Patent number: 7371386Abstract: The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and conserved with respect to the character of the amino acids. In many isolates, this motif falls between amino acids 401 to 406 or 407. The discovery of this motif allows for additional materials and methods to treat and diagnose HCV.Type: GrantFiled: September 18, 2006Date of Patent: May 13, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Amy J. Weiner, Michael Houghton
-
Patent number: 7361459Abstract: Methods for evaluating the antiviral activity of test compounds are provided. Further aspects of the methods involve the retroviral capsid protein of HIV-1. In another aspect, methods of reducing mortality associated with AIDS with a compound that binds to the apical cleft near the C-terminal end of the N-terminal domain of the HIV-1 capsid protein are provided. Derivatives of CAP-1, CAP-2, CAP-3, CAP-4, CAP-5, CAP-6 and CAP-7 are described that bind to the apical cleft of the N-terminal domain of the HIV-1 capsid protein and inhibit proper assembly of the core particle.Type: GrantFiled: April 22, 2003Date of Patent: April 22, 2008Assignee: University of Maryland, Baltimore CountyInventors: Michael F. Summers, Chun Tang, Mingjun Huang
-
Patent number: 7351526Abstract: A method for the diagnosis or detection of conformational diseases by assaying for a marker (the pathogenic conformer) of such diseases in a sample is described, which method comprises a cyclic amplification system to increase the levels of the pathogenic conformer which causes such diseases. In particular, such transmissible conformational diseases may be prion encephalopathies. Assays, diagnostic kits and apparatus based on such methods are also disclosed.Type: GrantFiled: June 13, 2001Date of Patent: April 1, 2008Assignee: Laboratories Serono SAInventors: Claudio Soto, Gabriella Saborio
-
Patent number: 7326416Abstract: Peptides comprising an Rpt1 domain of an INI1/hSNF5 which inhibit HIV-1 production in a human cell, and vectors encoding those peptides are provided. Also provided are methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by treating the cells with the above peptides or vectors. Other methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by inhibiting production of INI1/hSNF5 are provided. Additionally, methods of determining whether a test compound inhibits HIV-1 virion production in a mammalian cell, or spread of the HIV-1 to another cell, are provided. Those methods comprise determining whether the test compound inhibits the production of INI1/hSNF5 or disrupts the interaction of HIV-1 integrase with INI1/hSNF5.Type: GrantFiled: July 21, 2003Date of Patent: February 5, 2008Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Ganjam V. Kalpana
-
Patent number: 7320793Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: January 18, 2002Date of Patent: January 22, 2008Assignees: Cytos Biotechnology AG, Novartis Pharma AGInventors: Wolfgang A Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
-
Patent number: 7311907Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication competent helper virus.Type: GrantFiled: April 5, 2005Date of Patent: December 25, 2007Assignee: Genetix Pharmaceuticals, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Patent number: 7291723Abstract: The present application provides GB virus C sequences (GBV-C or hepatitis G virus) and methods of using the sequences.Type: GrantFiled: October 24, 2003Date of Patent: November 6, 2007Assignee: University of Iowa Research FoundationInventors: Jack T. Stapleton, Jinhua Xiang, Sarah George
-
Patent number: 7285642Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: GrantFiled: July 23, 2003Date of Patent: October 23, 2007Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard Herman Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 7279565Abstract: The exposure of cells, tissues and organs to “stress,” such as elevated temperature, stimulates production of active heat stress transcription factors (HSF), which in turn, induce expression of genes regulated by stress promoters. Normally, the activity of stress promoters declines after cells, tissues and organs are returned to a normal condition. The present invention relates to molecular circuits that provide for sustained expression of a gene of interest subsequent to a single application of stress.Type: GrantFiled: November 26, 2004Date of Patent: October 9, 2007Inventor: Richard Voellmy
-
Patent number: 7279165Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: GrantFiled: July 18, 2003Date of Patent: October 9, 2007Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Lūönd, Matthias Staufenbiel, Peter Frey
-
Patent number: 7264810Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: January 18, 2002Date of Patent: September 4, 2007Assignee: Cytos Biotechnology AGInventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
-
Patent number: 7256005Abstract: Disclosed are methods for screening that may be used to identify an inhibitor of HCV p7 protein. The methods may include incorporating an HCV p7 protein into a membrane to create an HCV p7-containing membrane that has an increased permeability relative to a membrane that does not contain HCV p7 protein. The HCV p7 protein may be contacted with a test compound, and the permeability of this HCV p7-containing membrane then may be compared to an HCV p7-containing membrane in which the HCV p7 protein has not been contacted with the test compound. The inhibitor of HCV p7 protein may be identified by observing a decrease in the permeability of the HCV p7-containing membrane in which the HCV p7 protein has been contacted with the test compound.Type: GrantFiled: September 23, 2003Date of Patent: August 14, 2007Assignee: The Chancellor, Masters and Scholars of the University of OxfordInventors: Nicole Zitzmann, Raymond Allen Dwek Frs
-
Patent number: 7238349Abstract: The invention provides a monovalent influenza vaccine comprising a low dose of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, in combination with an aluminium adjuvant. The invention also provides vaccine kits comprising a combination of a parenteral and a mucosal influenza vaccine, wherein the combined dose of antigen is no more than the conventional antigen dose. Also provided are methods for preparing the vaccines.Type: GrantFiled: September 27, 2000Date of Patent: July 3, 2007Assignees: SmithKline Beecham Biologicals, s.a., Saechsisches Serumwerk DresdenInventors: Erik D'Hondt, Norbert Hehme
-
Patent number: 7223535Abstract: Synthetic peptides immunoreactive with hepatitis A virus (HAV) antibodies are provided. The peptides are useful as laboratory reagents to detect or quantify HAV antibodies in biological samples in clinical or research-based assays and for inducing an immune response to HAV when administered to a human or animal. The peptides contain antigenic epitopes, modified antigenic epitopes or combinations of epitopes of the major structural capsid polypeptides or non-structural polypeptides of HAV and contain one or more molecules of the amino acid glutamine (Q) at the carboxyl end of the peptide, which enhances immunoreactivity and immunogenicity, particularly IgM antibody reactivity.Type: GrantFiled: December 16, 2003Date of Patent: May 29, 2007Assignee: Centers for Disease ControlInventors: Howard A. Fields, Yury E. Khudyakov
-
Patent number: 7220437Abstract: Compositions with antiviral and/or antibacterial activities comprising one or more ingredients from eight plants found in Ghana.Type: GrantFiled: October 18, 2001Date of Patent: May 22, 2007Inventor: Nana K. Ayisi
-
Patent number: 7208628Abstract: This invention relates to methods and compositions directed towards the diagnosis and treatment of Hepatitis C virus infection and the screening of potential therapeutic compounds using novel small molecules based on imidazole-4,5-dicarboxylic acids scaffolds.Type: GrantFiled: May 13, 2002Date of Patent: April 24, 2007Assignee: Kansas State University Research FoundationInventors: Scott C. Todd, Paul W. Baures
-
Patent number: 7208478Abstract: Immunostimulatory polynucleotide-immunomodulatory molecule conjugate compositions are disclosed. These compositions include a polynucleotide that is linked to an immunomodulatory molecule, which molecule comprises an antigen and may further comprise immunomodulators such as cytokines and adjuvants. The polynucleotide portion of the conjugate includes at least one immunostimulatory oligonucleotide nucleotide sequence (ISS). Methods of modulating an immune response upon administration of the polynucleotide-immunomodulatory conjugate preparation to a vertebrate host are also disclosed.Type: GrantFiled: March 20, 2003Date of Patent: April 24, 2007Assignee: The Regents of the University of CaliforniaInventors: Dennis A. Carson, Eyal Raz, Mark Roman